. 2019 May 31;98(22):e15749. doi: 10.1097/MD.0000000000015749
Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
Table 1.
Clinical trials of anti-angiogenic drugs were reported for recurrent GBM.
